Most of these studies reported an upregulation of proangiogenic factors like VEGF, PDGF, PlGF and HGF during therapy [23, 24, 29], which may reflect an increase of tumor hypoxia during antiangiogenic therapy. This evidence concerns the gene PGF and neoplasm.